Multiple Myeloma 2013
DOI: 10.1007/978-1-4614-8520-9_22
|View full text |Cite
|
Sign up to set email alerts
|

Amyloidosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
14
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(14 citation statements)
references
References 96 publications
0
14
0
Order By: Relevance
“…Usually, the isotype of the light chain produced is the λ light chain occurring in approximately 80% of cases ( Merlini, 2017 ). However, AL amyloidosis is not solely limited to the unnatural production of light chains and can sometimes, albeit infrequently, involve an overproduction of heavy chains or fragments ( Gertz & Zeldenrust, 2014 ). The light chain isotype may affect certain tissues more than others due to the variability in light chain sequencing, which may result in structural and biophysical differences.…”
Section: Pathophysiologymentioning
confidence: 99%
See 4 more Smart Citations
“…Usually, the isotype of the light chain produced is the λ light chain occurring in approximately 80% of cases ( Merlini, 2017 ). However, AL amyloidosis is not solely limited to the unnatural production of light chains and can sometimes, albeit infrequently, involve an overproduction of heavy chains or fragments ( Gertz & Zeldenrust, 2014 ). The light chain isotype may affect certain tissues more than others due to the variability in light chain sequencing, which may result in structural and biophysical differences.…”
Section: Pathophysiologymentioning
confidence: 99%
“…Patients with extensive plasma cell infiltration of greater than 30% do not usually present with typical myeloma symptoms (hypercalcemia, renal dysfunction, anemia, lytic lesions), but rather present with symptoms of organ damage, such as cardiac symptoms, nephrotic range proteinuria, dysphagia, peripheral neuropathy, fatigue, or GI symptoms ( Kastritis & Dimopoulos, 2015 ). Patients who do not have an initial concurrent diagnosis of MM will have a less than 1% likelihood of progressing to overt myeloma ( Gertz & Zeldenrust, 2014 ).…”
Section: Pathophysiologymentioning
confidence: 99%
See 3 more Smart Citations